Irini Karapanagiotou‐Schenkel

N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

Wolfgang Wick, Susan Dettmer, Anne Berberich et al. · Neuro-Oncology · 2018 · 145 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

Katrin Hoffmann, Tom M. Ganten, Daniel Gotthardtp et al. · BMC Cancer · 2015 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study

Anna Nikoghosyan, Irini Karapanagiotou‐Schenkel, Marc Münter et al. · BMC Cancer · 2010 · 79 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma

Claudia Blattmann, Susanne Oertel, Daniela Schulz–Ertner et al. · BMC Cancer · 2010 · 66 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag et al. · European Journal of Cancer · 2015 · 61 citations

Medicine, Oncology, Pharmacology +17